July 3, 2025 11:07 AM EDTUpdated July 3, 10:46 PM

Novartis' Cosentyx fails Phase 3 study for autoimmune disease

Max Gelman

Senior Editor

Novartis faced a setback in its ambition to expand its blockbuster drug Cosentyx and compete in an autoimmune condition with products from Roche and AbbVie …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Novartis' Cosentyx fails Phase 3 study for autoimmune disease

Max Gelman

Senior Editor

Sign up to read this article for free.

Updated: FDA publishes repository of 200+ drug rejection letters, promising more in the future

FDA hands Capricor a CRL for its Duchenne cell therapy

Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly

AbbVie inks $700M deal with IGI for multiple myeloma trispecific antibody

Century Therapeutics lays off half of its staff, CFO departs as it narrows priorities

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases

No­var­tis' Cosen­tyx fails Phase 3 study for au­toim­mune dis­ease

Max Gelman

Senior Editor

Sign up to read this article for free.

Up­dat­ed: FDA pub­lish­es repos­i­to­ry of 200+ drug re­jec­tion let­ters, promis­ing more in the fu­ture

FDA hands Capri­cor a CRL for its Duchenne cell ther­a­py

Biotech’s Q2 num­bers paint a pic­ture of the good, the bad and the ug­ly

Ab­b­Vie inks $700M deal with IGI for mul­ti­ple myelo­ma trispe­cif­ic an­ti­body

Cen­tu­ry Ther­a­peu­tics lays off half of its staff, CFO de­parts as it nar­rows pri­or­i­ties

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

Novartis' Cosentyx fails Phase 3 study for autoimmune disease

Updated: FDA publishes repository of 200+ drug rejection letters, promising more in the future

FDA hands Capricor a CRL for its Duchenne cell therapy

Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly

AbbVie inks $700M deal with IGI for multiple myeloma trispecific antibody

Century Therapeutics lays off half of its staff, CFO departs as it narrows priorities

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases